Aptinyx Inc (NASDAQ:APTX)’s stock price shot up 6.8% on Thursday . The stock traded as high as $3.97 and last traded at $3.94, 297,342 shares changed hands during trading. A decline of 14% from the average session volume of 347,107 shares. The stock had previously closed at $3.69.

A number of equities research analysts have recently commented on APTX shares. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Aptinyx in a research note on Thursday, June 18th. SunTrust Banks started coverage on Aptinyx in a research note on Wednesday, July 1st. They set a “buy” rating and a $15.00 target price on the stock. William Blair started coverage on Aptinyx in a research note on Thursday, May 7th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded Aptinyx from a “sell” rating to a “hold” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. Aptinyx presently has an average rating of “Buy” and an average price target of $7.81.

The firm has a market cap of $172.14 million, a PE ratio of -2.43 and a beta of 1.48. The stock has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $3.50.

Aptinyx (NASDAQ:APTX) last posted its earnings results on Thursday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.01). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $0.91 million. Aptinyx had a negative net margin of 1,540.42% and a negative return on equity of 47.99%. As a group, sell-side analysts predict that Aptinyx Inc will post -1.25 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Group AG grew its stake in shares of Aptinyx by 2,549.0% in the second quarter. UBS Group AG now owns 7,947 shares of the company’s stock worth $33,000 after acquiring an additional 7,647 shares during the last quarter. Spark Investment Management LLC grew its stake in shares of Aptinyx by 53.5% in the first quarter. Spark Investment Management LLC now owns 33,316 shares of the company’s stock worth $71,000 after acquiring an additional 11,616 shares during the last quarter. DCF Advisers LLC grew its stake in shares of Aptinyx by 15.9% in the first quarter. DCF Advisers LLC now owns 105,800 shares of the company’s stock worth $229,000 after acquiring an additional 14,500 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Aptinyx in the first quarter worth $32,000. Finally, Morgan Stanley grew its stake in shares of Aptinyx by 22.0% in the first quarter. Morgan Stanley now owns 89,189 shares of the company’s stock worth $193,000 after acquiring an additional 16,092 shares during the last quarter. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

About Aptinyx (NASDAQ:APTX)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: How to Invest in an Index Fund

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.